5J17

Solution structure of Ras Binding Domain (RBD) of B-Raf

  • Classification: PROTEIN BINDING
  • Organism(s): Homo sapiens
  • Expression System: Escherichia coli BL21(DE3)
  • Mutation(s): No 

  • Deposited: 2016-03-29 Released: 2016-10-05 
  • Deposition Author(s): Dutta, K., Vasquez-Del Carpio, R., Aggarwal, A.K., Reddy, E.P.
  • Funding Organization(s): National Institutes of Health/National Cancer Institute (NIH/NCI), Onconova Therapeutics Inc (OCI), National Institutes of Health/National Center for Research Resources (NIH/NCRR), National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 1024 
  • Conformers Submitted: 10 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.

Athuluri-Divakar, S.K.Vasquez-Del Carpio, R.Dutta, K.Baker, S.J.Cosenza, S.C.Basu, I.Gupta, Y.K.Reddy, M.V.Ueno, L.Hart, J.R.Vogt, P.K.Mulholland, D.Guha, C.Aggarwal, A.K.Reddy, E.P.

(2016) Cell 165: 643-655

  • DOI: 10.1016/j.cell.2016.03.045
  • Primary Citation of Related Structures:  
    5J17, 5J18, 5J2R

  • PubMed Abstract: 
  • Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers. The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein. Functional studies have shown that the switch region of RAS interacts with a large number of effector proteins containing a common RAS-binding domain (RBD) ...

    Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers. The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein. Functional studies have shown that the switch region of RAS interacts with a large number of effector proteins containing a common RAS-binding domain (RBD). Because RBD-mediated interactions are essential for RAS signaling, blocking RBD association with small molecules constitutes an attractive therapeutic approach. Here, we present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway. We also find that ribosertib binds to the RBDs of Ral-GDS and PI3Ks. These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.


    Organizational Affiliation

    Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA; Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA. Electronic address: ep.reddy@mssm.edu.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Serine/threonine-protein kinase B-rafA92Homo sapiensMutation(s): 0 
Gene Names: BRAFBRAF1RAFB1
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for P15056 (Homo sapiens)
Explore P15056 
Go to UniProtKB:  P15056
PHAROS:  P15056
GTEx:  ENSG00000157764 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP15056
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 1024 
  • Conformers Submitted: 10 
  • Selection Criteria: structures with the lowest energy 
  • OLDERADO: 5J17 Olderado

Structure Validation

View Full Validation Report




Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesCA158209
Onconova Therapeutics Inc (OCI)United States--
National Institutes of Health/National Center for Research Resources (NIH/NCRR)United StatesCO6RR015495
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesP41GM066354

Revision History  (Full details and data files)

  • Version 1.0: 2016-10-05
    Type: Initial release
  • Version 1.1: 2017-09-20
    Changes: Author supporting evidence, Structure summary
  • Version 1.2: 2019-12-04
    Changes: Author supporting evidence, Data collection